FDA has granted candidate CFT7455 from C4 Therapeutics orphan drug status. CFT7455 is being developed to treat multiple myeloma. The drug could also be used to treat non-Hodgkin's lymphoma, including peripheral T-cell lymphoma and mantle cell lymphoma. In June, the company initiated a phase 1/2 clinical trial in which it plans to enroll 160 participants.
FDA has granted candidate CFT7455 from C4 Therapeutics orphan drug status. CFT7455 is being developed to treat multiple myeloma. The drug could also be used to treat non-Hodgkin's lymphoma, including peripheral T-cell lymphoma and mantle cell lymphoma. In June, the company initiated a phase 1/2 clinical trial in which it plans to enroll 160 participants. 
ir.c4therapeutics.com
English (US) 